CytoMed Therapeutics Limited

Healthcare · Biotechnology · Singapore

Last price 0.9006 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.75M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural ...